Glaukos - GKOS Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GKOS shares.
View GKOS analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1-year price targets for Glaukos' stock. Their GKOS share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 10.1% and is now trading at $48.11.
View the best growth stocks for 2023 here.

Glaukos saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 4,370,000 shares, an increase of 5.3% from the December 15th total of 4,150,000 shares. Based on an average daily volume of 385,500 shares, the days-to-cover ratio is presently 11.3 days. Approximately 9.6% of the company's stock are short sold.
View Glaukos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our GKOS earnings forecast.

Glaukos Co. (NYSE:GKOS) announced its earnings results on Wednesday, November, 2nd. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.08. The medical instruments supplier had revenue of $71.27 million for the quarter, compared to analyst estimates of $67.88 million. Glaukos had a negative net margin of 31.45% and a negative trailing twelve-month return on equity of 16.16%.

Glaukos issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $278.00 million-$280.00 million, compared to the consensus revenue estimate of $278.63 million.

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by many different retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.26%), Peregrine Capital Management LLC (0.24%), Assenagon Asset Management S.A. (0.12%), State of Alaska Department of Revenue (0.07%), Yousif Capital Management LLC (0.06%) and Exchange Traded Concepts LLC (0.06%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $48.11.

Glaukos (NYSE:GKOS) has a market capitalization of $2.29 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

The company employs 727 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.